News

Telangana aims to make Hyderabad leading life sciences hub amid Centre’s Biopharma SHAKTI boostTelangana is set to emerge as a major beneficiary of the Biopharma SHAKTI scheme, led by its well-established industry clusters, robust research ecosystem, and strong manufacturing capabilities. It already houses leading global pharmaceutical companies, such as Amgen, Zoetis, Evernorth, HCA Healthcare, Eli Lilly and Sanofi.By CNBCTV18.com February 18, 2026, 1:51:23 PM IST (Published)2 Min ReadTelangana has emerged as a leading integrated life sciences hub, hosting more than 2,000 companies and contributing to almost 35% of India’s pharmaceutical production.

The state’s ‘Next-Gen Life Sciences Policy 2026-2030’ aligns with the Biopharma SHAKTI initiative announced in the Budget 2026 that aims at bolstering domestic production of biologics and biosimilars.

Last month, the state launched its Next-Gen Life Sciences Policy 2026-2030 at the World Economic Forum in Davos, Switzerland, with a focus on emerging areas like biologics and biosimilars.

Meanwhile, chief minister A Revanth Reddy on Tuesday, February 17, inaugurated BioAsia 2026, inviting top biopharma companies to establish their Global Capability Centres (GCCs) and invest in the city.

The state is set to emerge as a major beneficiary of the Biopharma SHAKTI scheme, led by its well-established industry clusters, robust research ecosystem, and strong manufacturing capabilities. It already houses leading global pharmaceutical companies, such as Amgen, Zoetis, Evernorth, HCA Healthcare, Eli Lilly and Sanofi.

The CM noted that several leading life sciences companies have already established GCCs in the city. Reddy also proposed the development of a dedicated zone for GCCs within Bharat Future City.

Major investments announced at the BioAsia 2026 in Hyderabad include global players like Opella Healthcare and Vaksindo Animal Health.

Opella Healthcare, headquartered in France, is expanding its GCC operations in Hyderabad. The company is setting up a 42,000 sq. ft. facility in the city, which is expected to generate up to 500 jobs over the next year. Meanwhile, Vaksindo Animal Health, which is a division of JAPFA Indonesia, is setting up a BSL-3 vaccine manufacturing facility in Genome Valley. The unit will manufacture vaccines for poultry, cattle, swine and aquaculture.

The Centre allocated ₹10,000 crore for the Biopharma SHAKTI initiative in the Union Budget 2026-27. In alignment with this objective, the Telangana government will earmark dedicated land within the expanded Genome Valley to support biocatalysis, precision fermentation, and next-generation biomanufacturing, all through its own life sciences policy.

“We recently launched our life sciences policy, which envisions Telangana as one of the world's top five life sciences clusters by 2030. Biologics and biosimilars manufacturing is one of our key areas of focus for the next five years,” director of industries, Government of Telangana, Nikhil Chakravarthi J, said.

Also Read: Telangana CM Revanth Reddy announces special zone for GCCs in Bharat Future CityContinue ReadingTagsHyderabadTelangana